23andMe Holding Co. (ME) Stock Price: $0.61+0.00 (+0.00%)
At close: Mar 19, 2026, 4:00 PM ET
The closing share price for 23andMe Holding Co. (ME) stock was $0.61 for Thursday, March 19, 2026, up 0.00% on the day.
Longer view (total return, dividends reinvested): past 12 months -67.1% · 3-year avg -76.3%/yr · 5-year avg -68.9%/yr
ME Price Chart
ME Key Metrics
See All MetricsME Earnings Preview
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.00
vs Estimate
$-2.43
Revenue
$25.42M
vs Estimate
$48.76M
ME Analyst Ratings
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.61
High
N/A
ME Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2023 | $-2.99 | $-2.99 | $-2.99 | 1 |
| Q3 2023 | $-2.81 | $-2.81 | $-2.81 | 1 |
| Q4 2023 | $-3.17 | $-2.80 | $-2.42 | 2 |
| Q1 2024 | $-3.32 | $-3.32 | $-3.32 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2024 | $-1.30 | $-1.30 | $-1.30 | 1 |
| FY 2025 | $-12.59 | $-12.59 | $-12.59 | 1 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2023 | $56.90M | $56.90M | $56.90M | 1 |
| Q3 2023 | $56.80M | $56.80M | $56.80M | 1 |
| Q4 2023 | $54.03M | $54.03M | $54.03M | 1 |
| Q1 2024 | $49.74M | $55.82M | $61.90M | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2024 | $199.19M | $199.19M | $199.19M | 1 |
| FY 2025 | $166.68M | $166.68M | $166.68M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
ME Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1ME | $15.31M | $0.61 | +0.00% | -67.07% | -68.93% | N/A |
ME Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage